Advertisement
Singapore markets open in 8 hours 8 minutes

  • Straits Times Index

    3,404.47
    -6.34 (-0.19%)
     

  • S&P 500

    5,566.85
    -0.34 (-0.01%)
     

  • Dow

    39,329.87
    -46.00 (-0.12%)
     

  • Nasdaq

    18,375.45
    +22.69 (+0.12%)
     

  • Bitcoin USD

    55,881.59
    -1,198.66 (-2.10%)
     

  • CMC Crypto 200

    1,194.02
    +27.90 (+2.39%)
     

  • FTSE 100

    8,193.49
    -10.44 (-0.13%)
     

  • Gold

    2,363.60
    -34.10 (-1.42%)
     

  • Crude Oil

    82.35
    -0.81 (-0.97%)
     

  • 10-Yr Bond

    4.2820
    +0.0100 (+0.23%)
     

  • Nikkei

    40,780.70
    -131.67 (-0.32%)
     

  • Hang Seng

    17,524.06
    -275.55 (-1.55%)
     

  • FTSE Bursa Malaysia

    1,611.02
    -5.73 (-0.35%)
     

  • Jakarta Composite Index

    7,250.98
    -2.40 (-0.03%)
     

  • PSE Index

    6,529.43
    +36.68 (+0.56%)
     

Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Stock Is Going Strong: Have Financials A Role To Play?

editorial-team@simplywallst.com (Simply Wall St)
·3-min read

Organogenesis Holdings' (NASDAQ:ORGO) stock is up by a considerable 11% over the past month. As most would know, fundamentals are what usually guide market price movements over the long-term, so we decided to look at the company's key financial indicators today to determine if they have any role to play in the recent price movement. Specifically, we decided to study Organogenesis Holdings' ROE in this article.

Return on equity or ROE is a key measure used to assess how efficiently a company's management is utilizing the company's capital. Put another way, it reveals the company's success at turning shareholder investments into profits.

See our latest analysis for Organogenesis Holdings

How To Calculate Return On Equity?

Return on equity can be calculated by using the formula:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

ADVERTISEMENT

So, based on the above formula, the ROE for Organogenesis Holdings is:

2.1% = US$5.8m ÷ US$278m (Based on the trailing twelve months to March 2024).

The 'return' refers to a company's earnings over the last year. So, this means that for every $1 of its shareholder's investments, the company generates a profit of $0.02.

Why Is ROE Important For Earnings Growth?

Thus far, we have learned that ROE measures how efficiently a company is generating its profits. We now need to evaluate how much profit the company reinvests or "retains" for future growth which then gives us an idea about the growth potential of the company. Assuming everything else remains unchanged, the higher the ROE and profit retention, the higher the growth rate of a company compared to companies that don't necessarily bear these characteristics.

A Side By Side comparison of Organogenesis Holdings' Earnings Growth And 2.1% ROE

As you can see, Organogenesis Holdings' ROE looks pretty weak. Even compared to the average industry ROE of 14%, the company's ROE is quite dismal. However, we we're pleasantly surprised to see that Organogenesis Holdings grew its net income at a significant rate of 40% in the last five years. We believe that there might be other aspects that are positively influencing the company's earnings growth. For example, it is possible that the company's management has made some good strategic decisions, or that the company has a low payout ratio.

We then compared Organogenesis Holdings' net income growth with the industry and we're pleased to see that the company's growth figure is higher when compared with the industry which has a growth rate of 16% in the same 5-year period.

past-earnings-growth
past-earnings-growth

The basis for attaching value to a company is, to a great extent, tied to its earnings growth. What investors need to determine next is if the expected earnings growth, or the lack of it, is already built into the share price. This then helps them determine if the stock is placed for a bright or bleak future. If you're wondering about Organogenesis Holdings''s valuation, check out this gauge of its price-to-earnings ratio, as compared to its industry.

Is Organogenesis Holdings Using Its Retained Earnings Effectively?

Given that Organogenesis Holdings doesn't pay any regular dividends to its shareholders, we infer that the company has been reinvesting all of its profits to grow its business.

Summary

Overall, we feel that Organogenesis Holdings certainly does have some positive factors to consider. Even in spite of the low rate of return, the company has posted impressive earnings growth as a result of reinvesting heavily into its business. That being so, a study of the latest analyst forecasts show that the company is expected to see a slowdown in its future earnings growth. To know more about the latest analysts predictions for the company, check out this visualization of analyst forecasts for the company.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com